Trevena, Inc. (NASDAQ:TRVN) Short Interest Up 114.3% in May

Trevena, Inc. (NASDAQ:TRVN) was the target of a large growth in short interest in the month of May. As of May 31st, there was short interest totalling 43,500 shares, a growth of 114.3% from the May 15th total of 20,300 shares. Based on an average daily volume of 172,900 shares, the days-to-cover ratio is presently 0.3 days. Approximately 0.2% of the shares of the company are short sold.

Institutional Investors Weigh In On Trevena

A hedge fund recently bought a new stake in Trevena stock. Armistice Capital LLC bought a new position in shares of Trevena, Inc. (NASDAQ:TRVN) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 797,714 shares of the biopharmaceutical company’s stock, valued at approximately $576,000. Armistice Capital LLC owned 4.61% of Trevena as of its most recent SEC filing. 13.56% of the stock is currently owned by hedge funds and other institutional investors.

Trevena Trading Up 5.0 %

Shares of TRVN traded up $0.02 during midday trading on Friday, reaching $0.42. The stock had a trading volume of 114,117 shares, compared to its average volume of 143,570. Trevena has a 52 week low of $0.30 and a 52 week high of $1.12. The company has a quick ratio of 3.60, a current ratio of 3.60 and a debt-to-equity ratio of 8.35. The firm’s 50 day moving average price is $0.40 and its 200-day moving average price is $0.53.

Trevena (NASDAQ:TRVN) last posted its quarterly earnings data on Wednesday, May 15th. The biopharmaceutical company reported ($0.36) EPS for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.01. The firm had revenue of $0.02 million during the quarter. On average, equities analysts anticipate that Trevena will post -1.29 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have issued reports on the company. HC Wainwright reduced their price target on Trevena from $9.00 to $5.00 and set a “buy” rating for the company in a research report on Thursday, May 16th. StockNews.com assumed coverage on Trevena in a research report on Sunday, June 9th. They set a “sell” rating for the company.

About Trevena

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.